Experimental drug fails mid-stage trial for Alzheimer's, Parkinson's

Denmark's NeuroSearch announced that its collaborator, Boehringer Ingelheim, has canceled a planned Phase III trial of NS2330 for Alzheimer's and Parkinson's after a mid-stage trial failed to hit its efficacy criteria. Boehringer Ingelheim dropped its development of the compound for Alzheimer's but has retained development rights for Parkinson's. Boehringer has been responsible for research costs in the studies, and NeuroSearch says the research setback won't have any affect on this year's financial performance.

- read this report from AFX for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.